

**MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence  
Data as of December 5, 2022**

**Visit Adherence: Completion of Procedures During Enrollment and Follow-up<sup>1</sup> by Site**

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
Participants Enrolled	33	31	30	30	30	33	30	217
1. Behavioral Assessment Required and Expected	138	145	147	119	116	142	112	919
Completed	137 (99.3%)	145 (100.0%)	147 (100.0%)	119 (100.0%)	114 (98.3%)	141 (99.3%)	112 (100.0%)	915 (99.6%)
Not Completed	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.7%)	1 (0.7%)	0 (0.0%)	4 (0.4%)
2. In-depth Interview Required and Expected	79	88	88	70	68	83	66	542
Completed	74 (93.7%)	88 (100.0%)	88 (100.0%)	69 (98.6%)	64 (94.1%)	81 (97.6%)	64 (97.0%)	528 (97.4%)
Not Completed	5 (6.3%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	4 (5.9%)	2 (2.4%)	2 (3.0%)	14 (2.6%)
3. Physical Examination Required and Expected	66	62	60	60	60	66	60	434
Completed	66 (100.0%)	62 (100.0%)	60 (100.0%)	60 (100.0%)	60 (100.0%)	66 (100.0%)	60 (100.0%)	434 (100.0%)
4. Rectal Examination Required and Expected	145	150	148	130	128	149	126	976
Completed	136 (93.8%)	150 (100.0%)	142 (95.9%)	120 (92.3%)	128 (100.0%)	140 (94.0%)	126 (100.0%)	942 (96.5%)
Partially Completed	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.2%)
Not Completed	9 (6.2%)	0 (0.0%)	6 (4.1%)	9 (6.9%)	0 (0.0%)	8 (5.4%)	0 (0.0%)	32 (3.3%)
5. NAAT (Pharyngeal) for GC/CT Required and Expected	56	59	60	47	47	59	47	375
Completed	53 (94.6%)	59 (100.0%)	57 (95.0%)	47 (100.0%)	46 (97.9%)	56 (94.9%)	47 (100.0%)	365 (97.3%)
Not Completed	3 (5.4%)	0 (0.0%)	3 (5.0%)	0 (0.0%)	1 (2.1%)	3 (5.1%)	0 (0.0%)	10 (2.7%)
6. NAAT (Urine) for GC/CT Required and Expected	56	59	60	47	47	59	47	375
Completed	53 (94.6%)	59 (100.0%)	57 (95.0%)	47 (100.0%)	46 (97.9%)	56 (94.9%)	46 (97.9%)	364 (97.1%)
Not Completed	3 (5.4%)	0 (0.0%)	3 (5.0%)	0 (0.0%)	1 (2.1%)	3 (5.1%)	1 (2.1%)	11 (2.9%)
7. Pregnancy Test Required and Expected (For participants who can get pregnant only)	6	0	0	0	0	2	0	8
Completed	5 (83.3%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	2 (100.0%)	0 (-%)	7 (87.5%)
Not Completed	1 (16.7%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	1 (12.5%)
8. Plasma for Archive Required and Expected	33	31	30	30	30	33	30	217
Completed	33 (100.0%)	31 (100.0%)	30 (100.0%)	30 (100.0%)	30 (100.0%)	33 (100.0%)	30 (100.0%)	217 (100.0%)
9. Syphilis serology Required and Expected	56	59	60	47	47	59	47	375

<sup>1</sup> Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence  
Data as of December 5, 2022**

**Visit Adherence: Completion of Procedures During Enrollment and Follow-up<sup>1</sup> by Site**

	<b>Birmingham</b>	<b>Blantyre</b>	<b>Chiang Mai</b>	<b>Hillbrow, WRHI</b>	<b>Lima,San Miguel</b>	<b>Pittsburgh</b>	<b>San Francisco</b>	<b>All Sites</b>
Completed	53 (94.6%)	59 (100.0%)	57 (95.0%)	47 (100.0%)	47 (100.0%)	56 (94.9%)	47 (100.0%)	366 (97.6%)
Not Completed	3 (5.4%)	0 (0.0%)	3 (5.0%)	0 (0.0%)	0 (0.0%)	3 (5.1%)	0 (0.0%)	9 (2.4%)

<sup>1</sup> Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence  
Data as of December 5, 2022**

**Visit Adherence: Completion of Procedures During Enrollment and Follow-up<sup>1</sup> by Site**

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
10. HIV-1/2 Test Required and Expected	89	90	90	80	77	92	77	595
Completed	86 (96.6%)	90 (100.0%)	87 (96.7%)	80 (100.0%)	77 (100.0%)	89 (96.7%)	77 (100.0%)	586 (98.5%)
Not Completed	3 (3.4%)	0 (0.0%)	3 (3.3%)	0 (0.0%)	0 (0.0%)	3 (3.3%)	0 (0.0%)	9 (1.5%)
11. NAAT (Pelvic) for GC/CT/Trichomonas Required and Expected (For participants with vagina or neovagina)	4	0	0	0	0	1	0	5
Completed	3 (75.0%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)	0 (-%)	4 (80.0%)
Not Completed	1 (25.0%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	1 (20.0%)
12. NAAT (Anorectal) for GC/CT Required and Expected	56	59	60	47	47	59	47	375
Completed	53 (94.6%)	59 (100.0%)	57 (95.0%)	47 (100.0%)	46 (97.9%)	55 (93.2%)	47 (100.0%)	364 (97.1%)
Not Completed	3 (5.4%)	0 (0.0%)	3 (5.0%)	0 (0.0%)	1 (2.1%)	4 (6.8%)	0 (0.0%)	11 (2.9%)

<sup>1</sup> Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.